Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up Following Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price gapped up prior to trading on Monday after HC Wainwright raised their price target on the stock from $47.00 to $130.00. The stock had previously closed at $65.20, but opened at $78.90. HC Wainwright currently has a buy rating on the stock. Dianthus Therapeutics shares last traded at $80.67, with a volume of 1,905,070 shares changing hands.

Several other research firms have also recently commented on DNTH. Wedbush lifted their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Jefferies Financial Group lifted their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Oppenheimer upped their target price on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Stifel Nicolaus set a $120.00 price target on Dianthus Therapeutics in a research note on Monday. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.67.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the Phase 3 CAPTIVATE CIDP trial — interim responder analysis met the company’s GO criteria (20 confirmed responders with fewer than 40 Part A completers); company will keep the 300mg S.C. Q2W dose and plans regulator engagement, a material clinical de‑risking event and the primary catalyst for the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: Analyst upgrades/price‑target increases — HC Wainwright raised its target to $130 (buy) and Truist raised its target to $110 (buy). Upgrades increase buy‑side visibility and can amplify momentum after positive trial news. Benzinga
• Neutral Sentiment: Conference call/webcast to discuss interim responder analysis — management hosted a call to provide details, giving investors more color on the result and regulator engagement plans (increases transparency but depends on call tone). Dianthus to Host Conference Call
• Neutral Sentiment: Press and valuation pieces are drawing attention — several articles are re‑evaluating DNTH’s valuation after strong share gains, which can attract momentum traders and long‑term reallocations. Investors.com Yahoo Finance
• Neutral Sentiment: Short‑interest data shows 0 shares (report appears to be an artifact) — this reported figure is not meaningful and should not be interpreted as bearish evidence.
• Negative Sentiment: Filed a proposed $400M underwritten public offering (plus up to $60M option) — large equity raises typically dilute existing holders; while proceeds can fund development and commercialization, the market often treats such filings as near‑term negative. Dianthus Announces Proposed $400M Offering
• Negative Sentiment: Q4 earnings miss — reported loss of $1.43/share vs. consensus of ~$0.98 and negative margins/ROE; weaker results can temper enthusiasm and help explain the need for a capital raise. Zacks: Q4 Loss, Miss

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the period. Vestal Point Capital LP grew its holdings in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. State Street Corp increased its position in Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Braidwell LP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $32,859,000. Finally, Polar Capital Holdings Plc purchased a new position in Dianthus Therapeutics in the third quarter valued at approximately $29,434,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of -22.77 and a beta of 1.56. The business’s 50-day simple moving average is $49.17 and its two-hundred day simple moving average is $41.17.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.